Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
Sponsor: AstraZeneca
This PHASE3 trial investigates Endometrial Cancer and Malignant Solid Tumour and is currently actively recruiting participants. AstraZeneca leads this study, which shows 6 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Oct 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jul 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Alessandria, Italy , Amberg, Germany , Amsterdam, Netherlands , Ann Arbor, United States , Ashdod, Israel , Athens, Greece , Austin, United States , Aviano, Italy , Avignon, France and 235 more locations